Precision Medicine Advances in Early Breast Cancer: The Role of Biomarkers in Neo/Adjuvant Therapy

Precision Medicine Advances in Early Breast Cancer: The Role of Biomarkers in Neo/Adjuvant Therapy

Wednesday, December 7, 2022 in San Antonio, TX
Dinner -- San Antonio Marriott Rivercenter, 7:00 PM CT
Salons ABF

Agenda

  • Welcome, Overview, Audience Polling Questions
  • Defining Subsets of Patients in EBC in the Era of Precision Medicine
  • Evaluating and Managing High-Risk Disease in HR+/HER2- EBC With and Without gBRCA
  • Panel Discussion I
  • Immune Checkpoint Inhibition and Targeted Therapy in Early TNBC
  • Panel Discussion II
  • Audience Question and Answer Session

Faculty

Chair
Joyce O’Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director, 
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Faculty
Melinda Telli, MD

Faculty
Tiffany A. Traina, MD

Associate Professor of Medicine
Weill Medical College 
Vice Chair, Oncology Care
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners caring for patients with early-stage breast cancer.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Appraise current/emerging published data and consensus-based guidelines to inform the use of biomarkers and genomic classifiers to assess risk of recurrence
  • Plan optimal neoadjuvant/adjuvant treatment strategies with approved targeted or immunotherapy agents for appropriate patients with EBC 
  • Develop strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to improve adherence and optimize outcomes
  • Identify patients with HR+/HER2- EBC eligible for enrollment on ongoing clinical studies investigating novel therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO), requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.